Article
Novel human SR-BI antibodies prevent infection and dissemination of HCV in vitro and in humanized mice.
Journal of hepatology - 1 Jul 2012
Lacek Krzysztof, Vercauteren Koen, Grzyb Katarzyna, Naddeo Mariarosaria, Verhoye Lieven, Słowikowski Marek Patryk, Fafi-Kremer Samira, Patel Arvind H, Baumert Thomas F, Folgori Antonella, Leroux-Roels Geert, Cortese Riccardo, Meuleman Philip, Nicosia Alfredo
Abstract excerpt
BACKGROUND & AIMS: Hepatitis C virus (HCV)-induced end-stage liver disease is currently the major indication for liver transplantation in the Western world. After transplantation, the donor liver almost inevitably becomes infected by the circulating virus and disease progression is accelerated in immune suppressed transplant patients. The current standard therapy, based on pegylated interferon and ribavirin,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
